Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024, for Kintara Therapeutics, Inc. (now operating as TuHURA Biosciences, Inc.). The Company is a clinical-stage biopharmaceutical firm focused on developing novel cancer therapies, primarily its lead candidate REM-001 for cutaneous metastatic breast cancer (CMBC). The filing reflects the Company's status prior to the consummation of a merger with TuHURA Biosciences, Inc., which closed on October 18, 2024, subsequent to the reporting period.
Key Financial Metrics
| Metric | Q3 2024 (in thousands) | Q3 2023 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,161) | $(2,962) |
| Net Loss Attributable to Common Stockholders | $(2,176) | $(3,137) |
| Research & Development Expenses | $252 | $1,859 |
| General & Administrative Expenses | $1,957 | $1,103 |
| Cash and Cash Equivalents (End of Period) | $3,020 | $216 |
| Net Cash Used in Operating Activities | $(1,889) | $(1,317) |
| Total Assets | $4,140 | $6,202 |
| Total Liabilities | $2,445 | $2,445 |
| Working Capital | $1,226 | $3,269 |
Note: The Company has no revenue and operates at a loss. Margins are not applicable.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 27% to $2.16 million from $2.96 million in the prior year quarter.
- R&D Expenses: R&D expenses dropped significantly by 86% (from $1.86 million to $0.25 million), primarily due to the termination of the VAL-083 development program in late 2023.
- G&A Expenses: General and administrative expenses increased by 77% (from $1.10 million to $1.96 million). This increase was driven by professional fees and special meeting costs associated with the merger transaction with TuHURA.
- Liquidity: Cash and cash equivalents increased to $3.02 million from $0.22 million at the end of the prior year quarter, though cash burn from operations remains high.
- Preferred Stock: All outstanding Series C Preferred Stock was automatically converted to common stock during the quarter.
Outlook, Risks, and Subsequent Events
Merger and Name Change
Subsequent to the quarter end, on October 18, 2024, the Company completed a merger with TuHURA Biosciences, Inc. The Company changed its name to TuHURA Biosciences, Inc. and its ticker symbol to "HURA." A 1-for-35 reverse stock split was effected. Former Kintara shareholders received Contingent Value Rights (CVRs) entitling them to approximately 1.54 million shares if specific clinical milestones for REM-001 are met by December 31, 2025.
Going Concern
The Company has disclosed substantial doubt about its ability to continue as a going concern within one year of the filing date. With an accumulated deficit of $162.05 million and no revenue, the Company requires significant additional funding to maintain clinical trials and operations. Management is pursuing financing alternatives, including equity issuance and strategic partnerships.
Clinical Progress
The Company re-initiated the REM-001 clinical study for CMBC following the receipt of an NIH grant. As of November 14, 2024, four patients had been treated, with enrollment expected to complete in Q4 2024.
Investor Verification Checklist
- Merger Integration: Verify the post-merger capital structure and the specific terms of the Contingent Value Rights (CVRs) regarding the REM-001 milestone.
- Cash Runway: Assess the sufficiency of the $3.02 million cash balance against the projected burn rate for the REM-001 trial and general operations.
- Going Concern Status: Review the Company's ability to secure additional financing given the explicit "substantial doubt" disclosure.
- Clinical Milestones: Monitor the enrollment progress of the REM-001 study to determine if the CVR milestone (10 patients enrolled and completing 8 weeks of follow-up) will be achieved by the December 31, 2025 deadline.
- Expense Trends: Evaluate if the elevated G&A expenses related to the merger are one-time costs or indicative of a new baseline operating cost.